Nexthera Capital LP grew its position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 66.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 340,100 shares of the company’s stock after acquiring an additional 135,600 shares during the period. Global Blood Therapeutics comprises approximately 4.1% of Nexthera Capital LP’s investment portfolio, making the stock its 9th biggest position. Nexthera Capital LP owned approximately 0.78% of Global Blood Therapeutics worth $9,302,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the business. Janus Henderson Group PLC acquired a new position in shares of Global Blood Therapeutics in the second quarter worth about $26,919,000. Sectoral Asset Management Inc raised its position in shares of Global Blood Therapeutics by 31.0% in the second quarter. Sectoral Asset Management Inc now owns 452,781 shares of the company’s stock worth $12,384,000 after acquiring an additional 107,199 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Global Blood Therapeutics by 211.7% in the second quarter. Goldman Sachs Group Inc. now owns 317,571 shares of the company’s stock worth $8,686,000 after acquiring an additional 215,690 shares during the period. HarbourVest Partners LLC acquired a new position in shares of Global Blood Therapeutics in the second quarter worth about $3,306,000. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Global Blood Therapeutics in the second quarter worth about $594,000. Institutional investors and hedge funds own 86.07% of the company’s stock.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the completion of the transaction, the insider now owns 143,255 shares in the company, valued at $4,297,650. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Deval L. Patrick sold 27,053 shares of Global Blood Therapeutics stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total transaction of $803,203.57. Following the transaction, the director now owns 12,053 shares of the company’s stock, valued at approximately $357,853.57. The disclosure for this sale can be found here. Insiders sold 36,053 shares of company stock valued at $1,073,204 in the last quarter. Company insiders own 5.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Global Blood Therapeutics, Inc. (GBT) Shares Bought by Nexthera Capital LP” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/global-blood-therapeutics-inc-gbt-shares-bought-by-nexthera-capital-lp/1610808.html.

Global Blood Therapeutics, Inc. (NASDAQ GBT) traded down 0.0606% on Thursday, hitting $32.3304. 320,259 shares of the company traded hands. Global Blood Therapeutics, Inc. has a 12 month low of $13.35 and a 12 month high of $41.15. The stock’s market cap is $1.41 billion. The stock’s 50-day moving average is $28.37 and its 200 day moving average is $29.63.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.55) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.06. During the same quarter last year, the firm posted ($0.58) earnings per share. Equities research analysts expect that Global Blood Therapeutics, Inc. will post ($2.44) earnings per share for the current fiscal year.

A number of research analysts have weighed in on the stock. ValuEngine upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Oppenheimer Holdings, Inc. assumed coverage on shares of Global Blood Therapeutics in a research report on Friday, August 4th. They set an “outperform” rating and a $53.00 price target for the company. BidaskClub upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Cowen and Company restated an “outperform” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a research report on Monday, August 14th. Finally, Wedbush restated an “ourperform” rating and set a $73.00 price target on shares of Global Blood Therapeutics in a research report on Monday, September 18th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $55.70.

Global Blood Therapeutics Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.